New Phase III patiromer data boost Relypsa's IPO prospects
This article was originally published in Scrip
Relypsa upped its chances for a successful launch into the US stock market on 10 October when president and CEO John Orwin said the company plans to file for US FDA approval of the hyperkalemia drug candidate patiromer (RLY5016) based on statistically significant results from Part B of a Phase III clinical trial. Relypsa, which has the only therapy in development to treat high potassium levels in the blood, believes that its data support chronic dosing.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.